Drugs / Tegio
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06241469 | Feb 2024 → Aug 2026 overdue | adenocarcinoma, gastric cancer, gastroesophageal cancer | Wu Jun | Not yet recruiting | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT03973008 Background | Mar 2019 → Feb 2024 | gastric adenocarcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT06368063 Comparator | May 2024 → Mar 2026 overdue | pancreas disorder | Xi'an Jiaotong University | Recruiting | No outcome recorded |
| — | NCT05742620 Background | Jun 2023 → Jul 2026 overdue | — | Xijing Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tegio | “Oxalis 130mg/m2 intravenous drip on day 1, tegio 80-120 mg daily, twice, half an hour after breakfast and dinner, for 14 consecutive days” NCT03973008 ↗3“SOX: Tegio: 100mg/day, continuous medication for 2 weeks, stop for 1 week;” NCT05742620 ↗ “Tegio capsules monotherapy” NCT06368063 ↗ |
| Route | Oral | “Take tegio capsules orally, 80mg/d, day 1-28, repeated every 6 weeks, administered until 6 months.” NCT06368063 ↗ |